Cargando…
Repurposing mesalazine against cardiac fibrosis in vitro
Cardiovascular diseases are exacerbated and driven by cardiac fibrosis. TGFβ induces fibroblast activation and differentiation into myofibroblasts that secrete excessive extracellular matrix proteins leading to stiffening of the heart, concomitant cardiac dysfunction, and arrhythmias. However, effec...
Autores principales: | Hoffmann, Maximilian, Kant, Theresa A., Emig, Ramona, Rausch, Johanna S. E., Newe, Manja, Schubert, Mario, Künzel, Karolina, Winter, Luise, Klapproth, Erik, Peyronnet, Rémi, Ravens, Ursula, El-Armouche, Ali, Künzel, Stephan R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892689/ https://www.ncbi.nlm.nih.gov/pubmed/33064167 http://dx.doi.org/10.1007/s00210-020-01998-9 |
Ejemplares similares
-
Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice
por: Newe, Manja, et al.
Publicado: (2021) -
Modeling atrial fibrosis in vitro—Generation and characterization of a novel human atrial fibroblast cell line
por: Künzel, Stephan R., et al.
Publicado: (2020) -
Investigation of mesalazine as an antifibrotic drug following myocardial infarction in male mice
por: Künzel, Stephan R., et al.
Publicado: (2023) -
Genetic Deletion of Polo-Like Kinase 2 Induces a Pro-Fibrotic Pulmonary Phenotype
por: Kant, Theresa A., et al.
Publicado: (2021) -
Human Atrial Fibroblast Adaptation to Heterogeneities in Substrate Stiffness
por: Emig, Ramona, et al.
Publicado: (2020)